Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (NCT06057402)
ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
🩺 Plain-English Summary (8th-Grade Level)
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Who can join: Review the eligibility criteria below.
Location: UCI Health - Irvine Infusion Pharmacy ACC — Irvine, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- UCI Health - Irvine Infusion Pharmacy ACC — Irvine, California
- UC Irvine Health — Orange, California
- UCI Health — Orange, California
- UCHealth Poudre Valley Hospital — Fort Collins, Colorado
- UCHealth Harmony — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
- Longs Peak Hospital — Longmont, Colorado
- UCHealth Longs Peak Medical Center — Longmont, Colorado
- UCHealth - Medical Center of the Rockies — Loveland, Colorado
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida
- University of Miami Hospital and Clinics Deerfield Beach — Deerfield Beach, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- University of Miami Hospital and Clinics - Griffin Cancer Research Building — Miami, Florida
- University of Miami Hospital and Clinics — Miami, Florida
- University of Michigan — Ann Arbor, Michigan
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) — Detroit, Michigan
- St. David's South Austin Medical Center — Austin, Texas
- Epworth Freemasons — Melbourne, Victoria
- Epworth Hospital — Richmond, Victoria
- Slade Pharmacy — Richmond, Victoria
- Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
- Cross Cancer Institute — Edmonton, Alberta
- McGill University Health Centre — Montreal, Quebec
- Peking University Third Hospital — Beijing, Beijing Municipality
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.